A process for producing a metallocycle metallocene comprising reacting a reactant metallocene which has a cyclopentadienyl group having an alkenyl group attached which has at least 3 carbon atoms with about 2 molar equivalents of an alkali metal alkyl having at least 4 carbon atoms, catalyst systems resulting from the combination of the metallocycle metallocene and an organic cocatalyst, and polymerization processes using such catalyst systems are disclosed.

Novel multicyclic erythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a formula ##STR1## pharmaceutical compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, as well as a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of formula...

The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.

Multicyclic aromatic compounds useful as complexing agents having the general formula: ##STR1## Methods of complexing and quantitating a component in a sample such as urea or guanidine are also disclosed.

Multicyclic nitrone spin trapping compounds capable of forming stable free radical spin adducts are provided as well as methods for their synthesis. The multicyclic nitrone spin trapping compounds can be reacted with a free radical, such as a hydroxy or hydroperoxy radical, in solution to form a spin adduct which is stable and readily detectable by electron paramagnetic resonance (EPR) spectroscopy. The multicyclic nitrone spin traps can be used to detect free radicals in a sample such as a biol...

This invention relates to polycyclic compounds containing two mono- and/or bicyclic rings and a basic tertiary amino group capable of forming an ammonium ion at biological pH and which reduces levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention.

This invention relates to polycyclic compounds containing two mono- and/or bicyclic rings and a basic tertiary amino group capable of forming an ammonium ion at biological pH and which reduces levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention. The compounds of this invention are describ...

Dental materials and associated methods are described based on multicyclic allyl sulphides with general Formula (I): ##STR00001## in which R.sup.1 is H or a C.sub.1-C.sub.10 alkyl radical; R.sup.2 is H or a C.sub.1-C.sub.10 alkyl radical; R.sup.3 is absent or is a C.sub.1-C.sub.20 alkylene radical which can be interrupted by O or S, a cycloaliphatic C.sub.4-C.sub.12 radical, a bicyclic C.sub.6-C.sub.12 radical, a C.sub.6-C.sub.14 arylene or C.sub.7-C.sub.20 alkylene arylene radical; R.sup.4 is a...

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered fo...

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.